Zhejiang Dayang Biology Technology Co.,Ltd.

Shenzhen Stock Exchange 003017.SZ

Zhejiang Dayang Biology Technology Co.,Ltd. EBITDA for the year ending December 31, 2023: USD 17.30 M

Zhejiang Dayang Biology Technology Co.,Ltd. EBITDA is USD 17.30 M for the year ending December 31, 2023, a -1.25% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Zhejiang Dayang Biology Technology Co.,Ltd. EBITDA for the year ending December 31, 2022 was USD 17.52 M, a -11.24% change year over year.
Zhejiang Dayang Biology Technology Co.,Ltd. EBITDA for the year ending December 31, 2021 was USD 19.73 M, a -3.03% change year over year.
Zhejiang Dayang Biology Technology Co.,Ltd. EBITDA for the year ending December 31, 2020 was USD 20.35 M, a 19.19% change year over year.
Zhejiang Dayang Biology Technology Co.,Ltd. EBITDA for the year ending December 31, 2019 was USD 17.07 M, a 11.97% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

Shenzhen Stock Exchange: 003017.SZ

Zhejiang Dayang Biology Technology Co.,Ltd.

CEO	Mr. Yanggui Chen
IPO Date	Oct. 26, 2020
Location	China
Headquarters	No. 22 Chaoyang Road
Employees	839
Sector	Materials
Industries Fertilizers Chemicals & Advanced Materials Cleaning Supplies Organic Foods Personal Care Pet Food Petrochemicals Plastics

Description

Zhejiang Dayang Biology Technology Co.,Ltd. engages in research and development, production, and sale of biological products, agricultural chemicals, and chemical in China and internationally. The company's products include food additive potassium carbonate, potassium carbonate, food additive potassium bicarbonate, potassium bicarbonate, agricultural grade ammonium chloride, and industrial grade ammonium chloride. It also offers chemical products, such as 2-chloro-6-fiuorobenzaldehyde, 2-chloro-6-fluorobenzyl chloride, and anisole products; veterinary APIs, including amprolium HCL; and veterinary drug premixes comprising enramycin premixes. The company was founded in 1976 and is based in Jiande, China.

Key trends

Past 5 years